

Indikation:	Studientitel:	Leiter klinische Prüfung:	Ansprechpartner:
Rheumatologie	AST-MOMA Hochdosis-Chemotherapie und autologe Retransfusion CD34-selektionierter peripherer Blutstammzellen bei progressiver systemischer Sklerose - Modifikation nach Manifestation.	Prof. Dr. med. Jörg Henes, Tübingen	Prof.Dr. med. Jörg Henes, Tübingen
Rheumatologie	M15-572 A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) - SELECT - PsA 1.	Prof.Dr. med. Jörg Henes, Tübingen	Prof.Dr. med. Jörg Henes, Tübingen
Rheumatologie	Toffife Tocilizumab for the Treatment of Familial Mediterranean Fever – A randomized, doubleblind, phase II proof of concept study.	Prof.Dr. med. Jörg Henes, Tübingen	Prof.Dr. med. Jörg Henes, Tübingen
Rheumatologie	Inflarx A randomized, double-blind, double-dummy, active-controlled, multicenter, 2-part Phase II Study on replacement of steroids by IFX-1 in active Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA).	Prof.Dr. med. Jörg Henes, Tübingen	Prof.Dr. med. Jörg Henes, Tübingen
Rheumatologie	Feasibility A Phase 2, randomized, double-blind, placebo-controlled study to test the efficacy and safety of KPL-301 in giant cell arthritis.	Prof.Dr. med. Jörg Henes, Tübingen	Prof.Dr. med. Jörg Henes, Tübingen

Rheumatologie	EFC15068 A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Sarilumab in patients with giant cell arteritis.	Prof.Dr. med. Jörg Henes, Tübingen	Prof.Dr. med. Jörg Henes, Tübingen
Rheumatologie	Reliance Real life non-interventional Study on long-term Outcome of Ilaris (canakinumab) treated CAPS Patients.	Prof.Dr. med. Jörg Henes, Tübingen	Prof.Dr. med. Jörg Henes, Tübingen
Rheumatologie	ASCORE Long-term experience with Abatacept Sub CutaneOus in Routine clinical practice. (Langfristige Erfahrungen mit Abatacept s.c. in der klinischen Routinepraxis).	Prof.Dr. med. Jörg Henes, Tübingen	Prof.Dr. med. Jörg Henes, Tübingen
Rheumatologie	NEXT A MULTI-CENTER, MULTINATIONAL, NONINTERVENTIONAL STUDY WITH CERTOLIZUMAB PEGOL IN COMPARISON TO ANY OTHER SUBCUTANEOUS TNF INHIBITOR IN TWO PARALLEL GROUPS IN BIOLOGIC NAIVE PATIENTS WITH RHEUMATOID ARTHRITIS.	Prof.Dr. med. Jörg Henes, Tübingen	Prof.Dr. med. Jörg Henes, Tübingen
Rheumatologie	ALTEA Abatacept – long-term real-life experience in psoriatic arthritis (PSA) in Germany: An observational study.	Prof.Dr. med. Jörg Henes, Tübingen	Prof.Dr. med. Jörg Henes, Tübingen
Rheumatologie	MOSAIC A PHASE 4, MULTICENTER, SINGLE-ARM, OPENLABEL STUDY TO EVALUATE THE IMPACT OF APREMILAST (CC-10004) ON MRI OUTCOMES IN SUBJECTS WITH PSORIATIC ARTHRITIS.	Dr. Theodoros Xenitidis, Tübingen	Dr. Theodoros Xenitidis, Tübingen

Rheumatologie	<p>I4V-MC-B009 A Multinational, Prospective, observational Study of the Effectiveness, Healthcare Resource Utilization and Costs in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic or Biologic Disease-Modifying Therapies.</p>	Prof.Dr. med. Jörg Henes, Tübingen	Prof. Dr. med. Jörg Henes, Tübingen
Rheumatologie	<p>CC-10004-PSA-013 A phase 4, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of apremilast (CC-10004) in subjects with early, oligoarticular psoriatic arthritis despite initial stable treatment with either non-steroidal anti-inflammatory drugs (NSAIDs) and/or \leq 1 conventional synthetic disease-modifying antirheumatic drugs (DMARD)</p>	Prof.Dr. med. Jörg Henes, Tübingen	Prof. Dr. med. Jörg Henes, Tübingen